BPC-157 Dosage Calculator

How BPC-157 Dosage Calculation Works

The BPC 157 dosage calculator on this page converts your target mcg dose to insulin syringe units based on your vial size and BAC water volume. BPC-157 is dosed in micrograms — much smaller amounts than GLP-1 peptides like semaglutide or retatrutide, which are dosed in milligrams.

1. Concentration (mcg/mL) = Vial size (mg) × 1,000 ÷ BAC water added (mL)
2. Units to draw = (Target dose in mcg ÷ Concentration) × 100 for U-100 syringe

Example: 10 mg vial + 2 mL BAC water = 5,000 mcg/mL. A 500 mcg dose = 500 ÷ 5,000 × 100 = 10 units on U-100 (0.10 mL). A 250 mcg dose = 5 units (0.05 mL). Enter your values above and the calculator handles the conversion instantly.

BPC-157 Dosing Reference Chart

Common BPC-157 doses and their syringe unit equivalents using a 10 mg vial with 2 mL BAC water (5,000 mcg/mL):

• 125 mcg/injection: 2.5 units on U-100 (0.025 mL) — twice daily = 250 mcg/day
• 250 mcg/injection: 5 units on U-100 (0.05 mL) — once or twice daily
• 500 mcg/day: 10 units on U-100 (0.10 mL) — most common single daily dose
• 1,000 mcg/day: 20 units on U-100 (0.20 mL) — higher research doses

At 5,000 mcg/mL, draws of 5 units or fewer introduce meaningful measurement error. If you need very small doses, consider adding more BAC water (e.g., 5 mL for 2,000 mcg/mL) so the draw lands in the 10–25 unit range. Use the peptide reconstitution calculator to model different concentrations.

Choosing BAC Water Volume for BPC-157

BPC-157 doses are small, which makes concentration choice especially important for accuracy:

• 10 mg vial + 2 mL BAC: 5,000 mcg/mL — 500 mcg = 10 units; 250 mcg = 5 units (borderline accurate).
• 10 mg vial + 5 mL BAC: 2,000 mcg/mL — 500 mcg = 25 units; 250 mcg = 12 units. Good choice.
• 10 mg vial + 10 mL BAC: 1,000 mcg/mL — 500 mcg = 50 units; 250 mcg = 25 units. Best accuracy.

For doses of 250 mcg or less, a 1,000 mcg/mL concentration (10 mL BAC water) gives the most measurable draws. The trade-off is a larger vial volume and slightly faster BAC water consumption.

Subcutaneous vs. Intramuscular Injection

BPC-157 can be injected subcutaneously (under the skin) or intramuscularly (into muscle). Subcutaneous injection into the abdominal fat layer is the most common approach for daily dosing — it is easier, less painful, and avoids muscle soreness. Some researchers use IM injection near an injury site, theorizing localized effects. The dose calculation is identical regardless of injection route.

BPC-157 vs. TB-500

BPC-157 and TB-500 are often stacked together in research protocols. BPC-157 is a 15-amino-acid peptide dosed in the 250–500 mcg/day range. TB-500 (Thymosin Beta-4) is a larger peptide dosed in the milligram range — typically 2–2.5 mg per injection, two to three times per week during a loading phase. Both require BAC water reconstitution and insulin syringe administration. See the TB-500 dosage calculator for TB-500-specific defaults.

BPC-157 Benefits and Research

BPC-157 is a 15-amino-acid peptide derived from a protein found in gastric juice. It has been studied extensively in animal models across a wide range of tissue types. The primary mechanisms identified in research include: increased angiogenesis (new blood vessel formation in healing tissue), upregulation of growth hormone receptor expression, anti-inflammatory signaling via multiple pathways, and promotion of nitric oxide synthesis in damaged tissue.

Animal research findings include accelerated healing of tendons and ligaments (including complete Achilles tendon transection models), improved gut healing in colitis and IBS models, neuroprotective effects in spinal cord and brain injury studies, and reduced joint inflammation. In tendon healing studies, BPC-157-treated animals recovered functional strength approximately 30–50% faster than controls. The peptide is not FDA-approved, and no human clinical trials have been published.

• Tendon and ligament healing: accelerated recovery in multiple animal transection models
• Gut healing: reduced colitis severity and mucosal repair in rodent models
• Angiogenesis: increased blood vessel formation at injury sites, improving nutrient delivery
• Anti-inflammatory: reduced pro-inflammatory cytokine expression in multiple tissue types
• GH receptor upregulation: increased sensitivity to endogenous growth hormone

Human data is entirely self-reported via online research communities. Users commonly report improved recovery from tendon and ligament injuries, reduced joint pain, and improved gut comfort. These reports are consistent with the animal research mechanisms but have not been verified in controlled trials.

BPC-157 Side Effects and Safety

BPC-157 demonstrates a favorable safety profile in animal toxicology studies, with no significant organ toxicity observed at research doses. Human self-reported side effects are rare and generally mild. Because no human clinical trials exist, the full safety profile in humans is unknown, and long-term effects have not been studied.

• Nausea — occasionally reported, typically mild and transient
• Injection site reactions — minor discomfort, bruising, or erythema at the injection site
• No established major toxicity — animal studies at multiples of research doses showed no significant adverse organ effects
• Unknown long-term effects — no studies longer than 12 weeks exist in any species at typical research doses

BPC-157 is not FDA-approved for human use. It is available legally as a research chemical. Use only under the supervision of a licensed healthcare provider who can monitor for adverse effects and contraindications based on your individual health status.

Storage and Safe Handling

Refrigerate reconstituted BPC-157 at 2–8°C and use within 28 days. Never freeze reconstituted peptide — freeze-thaw cycles degrade the amino acid chain. Lyophilized powder should be stored frozen at −20°C for long-term storage. Wipe the vial stopper with an alcohol swab before every draw, and use a fresh needle for each injection. Dispose of sharps in a puncture-resistant container.